The IDMC’s Recommendation to Unblind a Phase III Trial of Radium-223 in Combination with Abiraterone Acetate for Prostate Cancer

Breaking News about the ERA 223 Trial, a phase III trial of radium-223 in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded:

In early December 2017, the ERA 223 trial released safety concerns of the combination arm of abiraterone acetate and radium-223 of prostate cancer patients. The information released suggests that patients receiving radium-223 with abiraterone acetate had more incidences of bone fractures and deaths.

About The Author

E. David Crawford, MD

E. David Crawford is Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Denver (UCD) in Denver, Colorado. He is also the E. David Crawford Endowed Chair in Urologic Oncology at UCD. Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in Urology at the Good Samaritan Hospital in Cincinnati. He was subsequently awarded a Genitourinary Cancer fellowship with Dr. Donald G. Skinner at the University of California Medical Center in Los Angeles. Dr. Crawford is a nationally recognized expert in prostate cancer. The recipient of more than 69 research grants, he has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone-refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored more than 400 articles, which have been published in such journals as Urology, The New England Journal of Medicine, and the Journal of the National Cancer Institute. He has published five textbooks. He is also an editorial reviewer or consultant for a large number of publications, including Urology, Journal of Urology, The New England Journal of Medicine, Cancer, and the Journal of Clinical Oncology. He serves as Medical Editor of Grand Rounds in Urology. Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical AUA, he is a member of the Committee to Study Urologic Research Funding and the Prostate Cancer Clinical Trials Subcommittee. He currently serves on the board of governors, the GU committee, and the scientific advisory board of the Southwest Oncology Groups, and he chairs the national Prostate Conditions Education Council (PCEC).

The IDMC’s Recommendation to Unblind a Phase III Trial of Radium-223 in Combination with Abiraterone Acetate for Prostate Cancer

About The Author

E. David Crawford, MD

Join the GRU Community

You have Successfully Subscribed!

Join the GRU Community

You have Successfully Subscribed!

The IDMC’s Recommendation to Unblind a Phase III Trial of Radium-223 in Combination with Abiraterone Acetate for Prostate Cancer

About The Author

E. David Crawford, MD

Related Posts

To the Point: Focal or Definitive Therapy for Prostate Cancer: MRI vs. Mapping Part II

Timing and Optimization of Radium 223 in CRPC

Urinary Molecular Marker Tests in Bladder Cancer: An Overview of Cxbladder

Ask the Expert: What Are Some of the Challenges for Urologists Treating Metastatic Castrate Resistant Prostate Cancer Patients?

Join the GRU Community

You have Successfully Subscribed!

Join the GRU Community

You have Successfully Subscribed!